|

MK-1045 Clinical Trials

6 actively recruiting trials across 2 locations

No change since July 2026

Also known as: CN-201, CN201

Pipeline

Phase 1: 2Phase 1/2: 2Phase 2/3: 2

Top Sponsors

  • Merck Sharp & Dohme LLC4
  • MSD R&D (China) Co., Ltd.2

Indications

  • Cancer5
  • Systemic Lupus Erythematosus1
  • Lymphoma, Follicular1
  • Lymphoma, Large B-Cell, Diffuse1
  • Lupus1

Other4 trials

A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
Phase 1/2
A Clinical Study of MK-1045 in People With Lupus or Rheumatoid Arthritis (MK-1045-004)
Phase 1
A Clinical Trial of MK-1045 in People With B-cell Acute Lymphoblastic Leukemia (MK-1045-005)
Phase 2/3
A Study to Evaluate MK-1045 (CN201) in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (MK-1045-001/CN201-101)
Phase 1

Denver, Colorado1 trial

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

Colorado Blood Cancer Institute ( Site 7000)

Phase 1/2

Nashville, Tennessee1 trial

A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007)

SCRI Oncology Partners ( Site 7000)

Phase 2/3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.